Business
Medexus Pharmaceuticals to Present at the SNN Network Canada Virtual Event on Thursday, January 7, 2021
TORONTO, ON, CHICAGO, IL and MONTREAL, QC / ACCESSWIRE / January 4, 2021 / Medexus Pharmaceu...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus Pharmaceuticals to Present at the SNN Network Canada Virtual Event on Thursday, January 7, 2021TORONTO, ON, CHICAGO, IL and MONTREAL, QC / ACCESSWIRE / January 4, 2021 / Medexus Pharmaceuticals Inc. (\"Medexus\" or \"Company\") (TSXV:MDP) (OTCQX:MEDXF), a leading specialty pharmaceutical company with a strong North American commercial platform, today announced that it will be presenting at the SNN Network Canada Virtual Event on January 7th at 2:30PM EST. Ken d'Entremont, CEO, and Roland Boivin, CFO, will be hosting the presentation and answering questions from investors.To access the live presentation, please use the following information:SNN Network Canada Virtual Event 2021Date: Thursday, January 7, 2020Time: 2:30 PM Eastern Time (11:30 AM Pacific Time)|Webcast: https://www.webcaster4.com/Webcast/Page/2059/39315If you would like to book 1on1 investor meetings with Medexus, and to watch the Company's presentation, please make sure you are registered for the virtual event here: https://canada.snn.network/signup1on1 meetings will be scheduled and conducted via private, secure video conference through the conference event platform.The SNN Network Canada Virtual Event website is available here: https://canada.snn.network/If you can't make the live presentation, all company presentations \"webcasts\" will be available directly on the conference event platform on this link under the tab \"Agenda\": https://canada.snn.network/agendaNews Compliments of ACCESSWIREAbout Medexus PharmaceuticalsMedexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company's leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B - a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control b...